Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using FloraStilbene™ Immune Stimulator Through Res Nova Bio Subsidiary
Company Receives Institutional Review Board Approval for 10 Patient Proof of Concept Oncology Trial
March 06, 2023 09:00 AM Eastern Standard Time
ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) announced today plans to initiate ten patient proof-of-concept clinical trial aimed at demonstrating the ability of FloraStilbene™ to stimulate the immune system in advanced breast cancer patients.
The Company has previously been granted a patent on utilization of pterostilbene and pterostilbene compositions for synergy with cancer immunotherapy such as interleukin-21, as well as suppression of cancer derived immune inhibitory agent enzymes such as indolamine 2,3 dioxygenase2. By combining previous experiences with immune modulation, the Company announced the creation of a novel immune stimulatory adjuvant combining pterostilbene with RU-486, termed “FloraStilbene”. Preclinical data, for which intellectual property has been filed, demonstrated FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
“FloraStilbene™ represents a non-toxic approach to overcoming breast cancer induced immune suppression, which acts as a significant barrier to efficacy of oncology immunotherapy,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “I am eager to lead this clinical trial, which if successful, will serve as the basis for a new approach to increase efficacy of drugs such as Herceptin and checkpoint inhibitors.”
“Therapeutic Solutions International has been working on, and filing patents, in the area of cancer immunotherapy with internationally renowned opinion leaders such as Dr. Santosh Kesari since 2015,” said Famela Ramos, President and Chief Executive Officer of Res Nova Bio. “We are excited to leverage these deep and broad resources to rapidly enter the clinic to address such a major unmet medical need.”
“One of the guiding principles of our Company has been to bring hope to patients for which limited options exist,” said Timothy Dixon, President, and Chief Executive Officer of Therapeutic Solutions International. “We strongly believe that immuno-adjuvant approaches such as FloraStilbene™ will greatly increase the potency of numerous existing therapies, as well as reducing various toxicities.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com.
About Res Nova Bio, Inc.
Res Nova Bio is a San Diego Biotechnology Cancer Immunotherapy Company dedicated to addressing the unmet medical need in the treatment of advanced breast cancer. Our Company is a place where problems get solved and the lives, of our employees and our patients, are transformed. The Company’s corporate website is www.resnovabio.com.